Antimitochondrial Antibodies: from Bench to Bedside

Area of Science:

• Immunology
• Hepatology
• Autoimmunity

Background:

• Anti-mitochondrial antibodies (AMA) target the E2 subunits of 2-oxo acid dehydrogenase complexes (PDC-E2).
• AMA are highly specific biomarkers for primary biliary cholangitis (PBC), present in 90-95% of patients.
• AMA detection in asymptomatic individuals presents management challenges due to controversial clinical risk data for PBC development.

Purpose of the Study:

• To review the main characteristics of anti-mitochondrial antibodies (AMA).
• To explore the association of AMA with autoimmune diseases.
• To examine the association of AMA with various liver diseases.

Main Methods:

• Literature review focusing on anti-mitochondrial antibodies (AMA).
• Analysis of studies investigating AMA in primary biliary cholangitis (PBC).
• Examination of research on AMA in overlap syndromes, hepatic diseases, and autoimmune conditions.

Main Results:

• AMA are highly specific for PBC but found in <1% of healthy subjects.
• AMA are associated with overlap syndrome, NASH, viral hepatitis, Sjögren's syndrome, systemic sclerosis, and systemic lupus erythematosus.
• Emerging associations include inflammatory myositis and heart disease.

Conclusions:

• AMA are crucial diagnostic markers for PBC.
• AMA presence extends beyond PBC, indicating associations with diverse autoimmune and liver diseases.
• Further research is needed to clarify the clinical implications of AMA in asymptomatic individuals.